Interim phase 4 data support takhzyro® (lanadelumab) as an effective treatment to reduce attacks in hereditary angioedema patients

Osaka, japan & cambridge, mass.--(business wire)--aaaai interim phase 4 data support takhzyro® (lanadelumab) as an effective treatment to reduce attacks in hereditary angioedema patients

TAK Ratings Summary

TAK Quant Ranking